Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development

Drug Discovery & Development

Boehringer Ingelheim partners with TARGET to progress NASH research TARGET PharmaSolutions announced that Boehringer Ingelheim International has entered into a multi-year strategic partnership for TARGET-NASH.
Drug Research > Drug Discovery & Development > News
Alnylam, Vir to jointly advance RNAi therapeutics for infectious diseases Alnylam Pharmaceuticals has announced an exclusive licensing agreement with Vir Biotechnology for the development and commercialization of RNAi therapeutics for infectious diseases, including chronic hepatitis B virus (HBV) infection.
Drug Research > Drug Discovery & Development > News Takeda, HemoShear collaborate to develop drugs for liver diseases By PBR Staff Writer
Takeda has collaborated with HemoShear Therapeutics to discover and develop novel therapeutics for liver diseases such as nonalcoholic steatohepatitis (NASH).
Drug Research > Drug Discovery & Development > News
See more Drug Discovery & Development news

Latest Drug Discovery & Development News and Insight

View all Drug Discovery & Development news or find news targeted to your interests
Moleculin to collaborate with University of Bergen for immune stimulation drug
Moleculin Biotech has entered into an agreement to collaborate with the University of Bergen to expand research on inhibition of brain metastasis by its pre-clinical drug WP1066 and its ability to increase immune system response to cancer and suppression of tumor cell proliferation and survival.
Drug Research > Drug Discovery & Development > News
Moffitt researchers discover new targets for approved cancer drug
A team of researchers at Moffitt Cancer Center used cellular drug screening, functional proteomics and computer-based modeling to determine whether drugs with well-known targets may be repurposed for use against other biological targets.
Drug Research > Drug Discovery & Development > News
PanOptica secures $11m to advance clinical development novel topical anti-VEGF eye drop
PanOptica a private biopharmaceutical company focused on developing innovative ophthalmology therapies, announced that it has secured $11m in a series B financing.
Drug Research > Drug Discovery & Development > News
Visterra closes $46.7m series C financing to advance pipeline of precision antibody-based biological medicines
Visterra has completed a series C financing round raising a total of $46.7m, including a new extension totaling $23.6m.
Drug Research > Drug Discovery & Development > News
Ligand to acquire Crystal Bioscience
Ligand Pharmaceuticals has announced the signing of a merger agreement whereby Ligand will acquire Crystal, a leader in avian genetics and the generation of fully-human therapeutic antibodies.
Drug Research > Drug Discovery & Development > News
Recursion Pharmaceuticals raises $60m to industrialize drug discovery using artificial intelligence
Recursion Pharmaceuticals, a biotechnology company that combines innovative biological science with artificial intelligence to discover new therapeutics at scale, is announcing its $60m series B financing led by Data Collective (DCVC).
Drug Research > Drug Discovery & Development > News
View all Drug Discovery & Development news or find news targeted to your interests